Oral GLP-1 Dosing and Titration: How the Schedule Differs From Injections
Key Takeaways
- Oral and injectable GLP-1s use completely different dose numbers — 25 mg oral ≠ 25 mg injectable
- Oral Wegovy titration: 1.5 mg → 4 mg → 9 mg → 25 mg over ~16 weeks
- Injectable Wegovy titration: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg over ~16 weeks
- Foundayo (orforglipron) has its own titration ladder — not interchangeable with semaglutide doses
- Titration exists to minimize GI side effects — skipping steps increases nausea and dropout rates
One of the most confusing aspects of oral GLP-1 treatment is the dosing. The numbers look completely different from injectable doses, the titration schedule has different step sizes, and switching between formats isn't a simple 1:1 conversion. Here's how dosing works for each oral option and why the differences exist.
Why Oral Doses Are Higher
Injectable semaglutide at 2.4 mg delivers most of the drug directly into the bloodstream. Oral semaglutide at 25 mg puts far less into the bloodstream — roughly 1–2% after SNAC-enhanced absorption. The higher oral dose compensates for the low bioavailability, delivering approximately the same effective drug exposure as the injection.
This means 25 mg oral ≈ 2.4 mg injectable in terms of clinical effect. Do not compare the raw numbers — they measure different things.
Titration Schedules Side by Side
| Week | Oral Wegovy | Injectable Wegovy | Foundayo (orforglipron) |
|---|---|---|---|
| Weeks 1–4 | 1.5 mg | 0.25 mg | Starter dose |
| Weeks 5–8 | 4 mg | 0.5 mg | Step 2 |
| Weeks 9–12 | 9 mg | 1 mg | Step 3 |
| Weeks 13–16 | 25 mg | 1.7 mg | Step 4 |
| Week 17+ | 25 mg (maintenance) | 2.4 mg (maintenance)* | Maintenance dose |
*Injectable Wegovy can be increased to 7.2 mg (HD) for patients who plateau on 2.4 mg. Foundayo titration specifics depend on the prescribing protocol from LillyDirect or your provider.
Why Titration Matters
GLP-1 agonists work by slowing gastric emptying and affecting appetite centers in the brain. Starting at the full dose causes severe nausea, vomiting, and diarrhea in a significant percentage of patients — enough to make many quit treatment entirely.
The titration ladder lets your body adjust gradually. Each step increases the drug exposure by a manageable increment. Most patients who complete titration report that side effects peak in the first 1–2 weeks of each dose increase and then subside.
Skipping titration steps or starting at a higher dose than prescribed is one of the most common reasons patients abandon GLP-1 treatment. The side effects of jumping straight to a maintenance dose can be severe. Follow your provider's titration schedule even if you're eager for faster results — you'll get there with fewer GI problems.
Switching Between Oral and Injectable
If you're considering switching formats (e.g., from injectable to oral, or vice versa), there is no universally standardized conversion protocol. Your provider will typically:
- Assess your current dose and response
- Start you on the equivalent maintenance dose of the new format (e.g., 2.4 mg injectable → 25 mg oral)
- Monitor for side effects, since the absorption profile differs between formats
Some providers start at a lower dose of the new format to allow readjustment, even if you were stable on a maintenance dose in the other format.
MadeMed
Oral SemaglutideCompounded oral semaglutide in tablet form. Quarterly plan brings cost to $89/month; monthly refill is $119/month.
MadeMed
Oral TirzepatideCompounded oral tirzepatide tablets. Quarterly plan brings cost to $89/month; monthly refill is $119/month.
Oral and injectable GLP-1 doses use different numbers because of absorption differences — don't compare them directly. Titration takes roughly the same amount of time (12–16 weeks) regardless of format. The most important thing is following the schedule your provider prescribes and reporting side effects early so adjustments can be made.
Titration schedules are approximate and may be adjusted by your healthcare provider based on tolerance and response. Never modify your dose without medical guidance.